Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.76 |
| ▸ | TSHR | P16473 | 3/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | THPO | P40225 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19799156 | 0.99 | ADORA3 (0.79) | ADORA2AADORA3ADORA2BADORA1MEN1 | |
| SCHEMBL12192981 | 0.99 | ADORA3 (0.79) | ADORA2AADORA3ADORA2BADORA1MEN1 | |
| SCHEMBL8604493 | 0.92 | ADORA3 (0.68) | ADORA2AADORA3ADORA2BADORA1MEN1 | |
| SCHEMBL8604498 | 0.92 | ADORA3 (0.68) | ADORA2AADORA3ADORA2BADORA1MEN1 | |
| SCHEMBL9352985 | 0.90 | MEN1 (0.77) | ADORA2AADORA3ADORA2BADORA1MEN1 | |
| SCHEMBL9352997 | 0.89 | MEN1 (0.76) | ADORA2AADORA3ADORA2BADORA1MEN1 | |
| SCHEMBL9353007 | 0.89 | MEN1 (0.76) | ADORA2AADORA3ADORA2BADORA1MEN1 | |
| SCHEMBL6660828 | 0.89 | ADORA3 (0.81) | ADORA2AADORA3ADORA2BADORA1MEN1 | |
| SCHEMBL6660843 | 0.89 | ADORA3 (0.81) | ADORA2AADORA3ADORA2BADORA1MEN1 | |
| SCHEMBL26487693 | 0.89 | ADORA3 (0.64) | ADORA2AADORA3ADORA2BADORA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED | 2011-08-25 | — | — | US | claimed |
| CN-102159209-A | The treatment of hearing loss | AUCKLAND UNISERVICES LTD | 2011-08-17 | — | — | CN | claimed |
| EP-2328577-A1 | THE TREATMENT OF HEARING LOSS | Auckland UniServices Limited (NZ) | 2011-06-08 | — | — | EP | claimed |
| WO-2010019057-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-02-18 | — | — | WO | claimed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED | 2011-08-25 | — | — | US | disclosed |
| CN-102159209-A | The treatment of hearing loss | AUCKLAND UNISERVICES LTD | 2011-08-17 | — | — | CN | disclosed |
| EP-2328577-A1 | THE TREATMENT OF HEARING LOSS | Auckland UniServices Limited (NZ) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010019057-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | ADORA2A 126/4885ADORA3 180/4885ADORA2B 48/4885 |
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA3 3/4885ADORA2B 4/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | ADORA2A 126/4885ADORA3 180/4885ADORA2B 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.